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Up to 25 million patients undergo high-risk surgical procedures each year 
worldwide, of whom 3 million do not survive until hospital discharge (1). A large 
proportion of these patients will have emergency laparotomy to gain access to 
the abdominal cavity. This procedure carries a high risk of death, often in the 
region of 20-30% mortality, many times due to sepsis (2)(3)(4). 
Intravenous immunoglobulin use has been proposed as an adjunctive treatment 
of postoperative sepsis not only to neutralize bacterial toxins (endotoxin and 
exotoxin) and to increase serum bactericidal action but also for modulation of 
cytokine release and its immunomodulatory effect (5). Immunomodulatory and 
anti-inflammatory mechanisms of immunoglobulins may reflect the involvement 
of several biological pathways, including a) decrease in the production of 
proinflammatory cytokines, b) suppression or neutralization of autoantibodies, c) 
down-regulation of adhesion molecules and chemokines, d) neutralization of 
superantigens and e) activated complement components and f) modulation of 
maturation and function of dendritic cells (6).  
Intravenous immunoglobulins have been used with mixed results in postoperative 
sepsis and in this issue of the Journal Tagami et al. (2015) provide another 
important jigsaw to the picture (7). In their propensity-matched analysis of 2161 
patients from the Japanese Diagnosis Procedure Combination database, they 
failed to show any beneficial effect of intravenous immunoglobulin therapy 
started on the first postoperative day, following emergency gastrointestinal 
surgery complicated with severe sepsis.  
Whilst their results are in line with recent clinical effectiveness analyses on the 
field, their efforts are laudable to evaluate current clinical practice in Japan (8). 
The meticulous clinical description of the patients in both the immunoglobulin and 
placebo treated group shows that the use of polyvalent immunoglobulin 
preparations in the current setting is ineffective and costly, however it also 
highlights the importance of the unknown and unmeasured immunological 
variability of their un-stratified population, which could be attributable for the 
negative results (7). 
It has been shown that immunoglobulin levels decrease in severe sepsis. In a 
recent study by Giamarellos-Bourboulis et al. (2013) all patients produced much 
lower IgM than healthy volunteers; this defect was exaggerated in septic shock 
(9). In our own observations, including patients with abdominal sepsis after 
emergency surgery, we observed similar decrease in plasma immunoglobulin 
levels, particularly IgM, whereas patients without infection did not show a 
significant decrease as compared to healthy individuals (courtesy of Heurich-
Sevcenco, unpublished data, personal communication). 
Considering the key role of the immune system in sepsis, immunomodulation, for 
instance replacing immunoglobulins to blunt the hyperinflammatory response and 
enhance bacterial clearence, could be effective in postoperative sepsis, however 
the clinical trials, including the current analysis of Tagami et al. have been 
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unconvincing (7)(10)(11).  
Until recently, immunomodulatory approaches have focused on suppressing the 
immune system, based on the assumption that an overwhelming inflammatory 
response was the primary cause of death in sepsis (12-14). Interestingly, careful 
examination of recent investigations outline that both pro-inflammatory and anti-
inflammatory responses occur early and parallel in sepsis, although the net initial 
effect of these competing processes is typically manifested by an early, 
hyperinflammatory phase characterized by vasodilatation resulting in shock, 
elevated core temperature and increased metabolism (15). Results of studies of 
circulating cytokines in patients showed that, in addition to pro-inflammatory 
cytokines, concentrations of potent anti-inflammatory cytokines such as 
interleukin-10 were increased early on (15)(16). 
In a very elegant longitudinal observation, Gomez et al. (2014) showed that in 
patients admitted to the ICU with severe sepsis, both pro- and anti-inflammatory 
responses (such as IL-6, TNF-alpha rise, monocyte HLA-DR expression 
reduction and IL-10 rise) were observed simultaneously during the course of the 
disease (16). These findings provide further evidence against the argument that 
the inflammatory response comes in waves, with a pro-inflammatory response 
preceding the anti-inflammatory response. The immune system probably evolved 
to activate both activities at the same time to assure that the pro-inflammatory 
response is attenuated in a timely manner to avoid secondary detrimental 
consequences. However, both activities, which may be simultaneous at the 
transcriptional level, are potentially different at the translational level by 
displaying various cytokine and chemokine kinetics, different affinity constants for 
receptors, and an interaction with co-factors. Thus, their biological activities may 
be different, and prediction exclusively based on the transcriptome may not be 
completely translated to the functional level (17). 
Indeed, in our own recent observations we found that patients with early onset 
severe sepsis were profoundly immunosuppressed on the day of ICU admission 
on the basis of monocyte HLA-DR expression and also on chemokine response 
(i.e. IL8/CXCL8, a typical neutrophil chemoattractant; and MCP1/CCL1, a 
monocyte and neutrophil chemoattractant) (18). The extent of the 
immunosuppression varied with the microbial component and chemokine tested 
and, critically, also varied between patients (18). This functional 
immunosuppressed state was observed despite measuring the normal 
hyperexpressed proinflammatory cytokine levels (e.g. IL-6 and IL-8) from the 
same samples (18). 
Major surgery is known to result in a transient suppression of various immune 
functions, including T-cell cytokine production and monocyte expression of HLA 
class II antigens (19). It therefore appears conceivable that postoperative 
immunosuppression may contribute to defective monocyte functions in patients 
with sepsis. Indeed, Weighardt and colleagues (2000) shown that postoperative 
sepsis was associated with defects in production of both pro- inflammatory and 
anti-inflammatory cytokines. Interestingly, in their study survival correlated with 
recovery of inflammatory but not anti-inflammatory responses (19).  
Based on the properties and mechanism of action of the immunoglobulins 
discussed above, it is therefore not surprising that Tagami et al. (2015) could not 
show any beneficial effect of the treatment, even when it was started very early in 
the septic process (7). The failure to show the benefits of immunoglobulin 
therapy in this study, and other high-profile trials aimed at blocking inflammatory 
mediators or pathogen recognition, demonstrates the need for a re-evaluation of 
the immunomodulatory approaches to sepsis (7)(12)(13). The focus of recent 
research has shifted to reflect this: therapies aimed at enhancing immune 
responsiveness in immunosuppressed sepsis patients are now being evaluated 
(e.g., GM-CSF, IFNγ) in animal models and in small scale clinical trials (20)(21). 
We have recently reported a novel strategy to boost the immune response by 
using Toll-like receptor (TLR)-derived peptides that target the TLR co-receptor 
CD14, enhancing its activity (18). This strategy is based on the fact that optimal 
TLR-mediated responses to most microbial components require engagement of 
CD14, which is expressed at the cell surface (mainly monocytes, macrophages 
and neutrophils) and as a soluble co-receptor (sCD14) in plasma and other 
biological fluids (18). The therapeutic potential of targeting CD14 with TLR2-
derived peptides was highlighted by the peptides’ ability to rescue the pro-
inflammatory response and restoring at least in part the pre-morbid 
responsiveness of immune cells to microorganisms of immunosuppressed sepsis 
patients’ whole blood in vitro (18). 
Notably, our data points to the existence of inter-subject variations in the immune 
response to infection, which may reflect differing susceptibility to secondary 
infections among the immunosuppressed sepsis patients. It also shows 
variations among patients in their sensitivity to the novel therapeutic strategy (18). 
This also highlights one flaw in the Tagami study: the decision to administer 
immunoglobulins was based solely on clinical parameters such as diagnosis of 
septic shock by the treating physician, which have repeatedly been shown to be 
inadequate stratification tools (7)(22). Indeed, previous clinical trials on the field 
were, for the most part, designed without stratification of patients (11).  
A prerequisite for the application of immunotherapy, either against the 
proinflammatory response or to reverse immunoparalysis in sepsis, is the 
appropriate stratification of patients (23). Various biomarkers should help in 
deciphering whether an individual is in the hyperinflammatory versus the 
hypoinflammatory phase of the disorder. Indeed, immunotherapy could worsen 
the outcome by causing an over-exuberant inflammatory response if applied 
during the wrong phase (23). 
Since biomarkers of compromised immune functions in sepsis, often are related 
to one mechanism of immunoparalysis, it is not plausible that a single marker can 
act as a completely reliable biological tool to guide immunotherapy. It has been 
shown that single biomarkers’ effectiveness is in many instances limited, by a 
lack of specificity and sensitivity to distinguish the presence of an infection and to 
stratify patients into homogenous groups for targeted treatment. Biomarker panel 
based models offer a tool to facilitate early diagnosis, in identifying patient 
populations at high risk of complications, and in monitoring progression of the 
disease, which are critical assessments for appropriate therapy and improvement 
in patient outcomes. Wong et al (2014) recently described a multi-biomarker 
panel which improved outcome stratification in septic shock (22). The use of such 
panel amongst the patients investigated by Tagami et al (2015) and others could 
exclude the lowest risk patients who are likely to survive without experimental 
intervention and also exclude the highest risk patients unlikely to survive with any 
therapy.  
Whilst the evidence is tilting towards to the use of immunostimulants, rather than 
anti-inflammatory therapies like the immunoglobulins, in further clinical trials, an 
appropriate stratification is mandatory to enhance the potential for measurable 
risk reduction among moderate or high-risk patients with modifiable outcomes.  
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